A butyrate ingredient marketed as BIOMEnd by NutraShure was associated with greater pharmacokinetic performance and subjective self-reported measures of well-being, in a clinical study published in the Journal of Exercise and Nutrition.

The study included a group of 10 healthy adult men between the ages of 25 and 45 who ingested one of three butyrate forms, with blood samples and assessments collected over a 3.5-hour post-ingestion period. Measurements included serum butyrate concentrations, feelings of well-being, and physiological vitals. Blood samples were collected at six time points and analyzed using GC-MS (gas chromatography-mass spectrometry) techniques to measure serum butyrate levels. The researchers also measured participants’ self-reported mood, motivation, and concentration via Visual Analog Scale questionnaires.

BIOMEnd had significantly higher peak plasma concentrations (Cmax) and a quicker time to maximum concentration (Tmax) compared to tributyrin, indicating greater bioavailability and faster systemic circulation. The small group of participants also reported greater feelings of well-being, calmness, and motivation after ingesting BIOMEnd. BIOMEnd achieved a 500% greater Cmax than tributyrin and a 180% greater Cmax than sodium butyrate.

“This study is the first comparative study of three commercially available forms of butyrate,” said Brandon Sojka, CEO of NutraShure. “The exceptional pharmacokinetic advantage of BIOMEnd, coupled with our new substantiated GLP-1 claims and superior delivery form, allows us to provide a truly innovative solution for supporting gut health, weight management, and overall well-being.”